Galle PR - Search Results

1

Heterogeneity of patients with intermediate (BCLC B) Hepatocellular Carcinoma: proposal for a subclassification to facilitate treatment decisions.

Bolondi L, Burroughs A, Dufour JF, Galle PR, Mazzaferro V, Piscaglia F, Raoul JL, Sangro B. Bolondi L, et al. Among authors: galle pr. Semin Liver Dis. 2012 Nov;32(4):348-59. doi: 10.1055/s-0032-1329906. Epub 2013 Feb 8. Semin Liver Dis. 2012. PMID: 23397536 Review.

2

CD95-induced apoptosis in human liver disease.

Galle PR, Krammer PH. Galle PR, et al. Semin Liver Dis. 1998;18(2):141-51. doi: 10.1055/s-2007-1007150. Semin Liver Dis. 1998. PMID: 9606811 Review.

3

Sorafenib in advanced hepatocellular carcinoma.

Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, de Oliveira AC, Santoro A, Raoul JL, Forner A, Schwartz M, Porta C, Zeuzem S, Bolondi L, Greten TF, Galle PR, Seitz JF, Borbath I, Häussinger D, Giannaris T, Shan M, Moscovici M, Voliotis D, Bruix J; SHARP Investigators Study Group. Llovet JM, et al. Among authors: galle pr. N Engl J Med. 2008 Jul 24;359(4):378-90. doi: 10.1056/NEJMoa0708857. N Engl J Med. 2008. PMID: 18650514 Free article. Clinical Trial.

4

Novel inhibitors in development for hepatocellular carcinoma.

Wörns MA, Galle PR. Wörns MA, et al. Among authors: galle pr. Expert Opin Investig Drugs. 2010 May;19(5):615-29. doi: 10.1517/13543781003767418. Expert Opin Investig Drugs. 2010. PMID: 20374038 Review.

5

Future perspectives in hepatocellular carcinoma.

Wörns MA, Galle PR. Wörns MA, et al. Among authors: galle pr. Dig Liver Dis. 2010 Jul;42 Suppl 3:S302-9. doi: 10.1016/S1590-8658(10)60521-X. Dig Liver Dis. 2010. PMID: 20547319 Review.

6

Sunitinib in patients with advanced hepatocellular carcinoma after progression under sorafenib treatment.

Wörns MA, Schuchmann M, Düber C, Otto G, Galle PR, Weinmann A. Wörns MA, et al. Among authors: galle pr. Oncology. 2010;79(1-2):85-92. doi: 10.1159/000320363. Epub 2010 Nov 12. Oncology. 2010. PMID: 21071995

7

Sorafenib for recurrence of hepatocellular carcinoma after liver transplantation.

Weinmann A, Niederle IM, Koch S, Hoppe-Lotichius M, Heise M, Düber C, Schuchmann M, Otto G, Galle PR, Wörns MA. Weinmann A, et al. Among authors: galle pr. Dig Liver Dis. 2012 May;44(5):432-7. doi: 10.1016/j.dld.2011.12.009. Epub 2012 Jan 20. Dig Liver Dis. 2012. PMID: 22265328

8

Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: subanalyses of a phase III trial.

Bruix J, Raoul JL, Sherman M, Mazzaferro V, Bolondi L, Craxi A, Galle PR, Santoro A, Beaugrand M, Sangiovanni A, Porta C, Gerken G, Marrero JA, Nadel A, Shan M, Moscovici M, Voliotis D, Llovet JM. Bruix J, et al. Among authors: galle pr. J Hepatol. 2012 Oct;57(4):821-9. doi: 10.1016/j.jhep.2012.06.014. Epub 2012 Jun 19. J Hepatol. 2012. PMID: 22727733 Free article. Clinical Trial.

9

The impact of patient and tumour baseline characteristics on the overall survival of patients with advanced hepatocellular carcinoma treated with sorafenib.

Wörns MA, Koch S, Niederle IM, Marquardt JU, Nguyen-Tat M, Gamstätter T, Schuchmann M, Schulze-Bergkamen H, Galle PR, Weinmann A. Wörns MA, et al. Among authors: galle pr. Dig Liver Dis. 2013 May;45(5):408-13. doi: 10.1016/j.dld.2012.10.010. Epub 2012 Nov 21. Dig Liver Dis. 2013. PMID: 23182599

10

Survival analysis of proposed BCLC-B subgroups in hepatocellular carcinoma patients.

Weinmann A, Koch S, Sprinzl M, Kloeckner R, Schulze-Bergkamen H, Düber C, Lang H, Otto G, Wörns MA, Galle PR. Weinmann A, et al. Among authors: galle pr. Liver Int. 2015 Feb;35(2):591-600. doi: 10.1111/liv.12696. Epub 2014 Oct 31. Liver Int. 2015. PMID: 25290314

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

823 results

Search Page